Preventive or therapeutic agent for inflammatory bowel...

Details Preventive or therapeutic agent for inflammatory bowel... Preventive or therapeutic agent for inflammatory bowel...

2003-10-03

2010-11-02

Mertz, Prema (Department: 1646)

Drug, bio-affecting and body treating compositions

Immunoglobulin, antiserum, antibody, or antibody fragment,...

C424S133100, C424S134100, C424S139100, C514S885000

Reexamination Certificate

active

07824674

ABSTRACT:
A preventive or therapeutic agent for inflammatory bowel disease such as Crohn's disease and ulcerative colitis said agent comprising as an active ingredient an interleukin-6 (IL-6) antagonist such as an antibody directed against IL-6 receptor.

REFERENCES:
patent: 5210075 (1993-05-01), Scholz et al.
patent: 5530101 (1996-06-01), Queen et al.
patent: 5670373 (1997-09-01), Kishimoto
patent: 5851793 (1998-12-01), Kishimoto
patent: 5888510 (1999-03-01), Kishimoto et al.
patent: 6428979 (2002-08-01), Kishimoto
patent: 6723319 (2004-04-01), Ito et al.
patent: 2002/0187150 (2002-12-01), Mihara et al.
patent: 2003/0236260 (2003-12-01), Shimojo et al.
patent: 2004/0115197 (2004-06-01), Yoshizaki et al.
patent: 2006/0292147 (2006-12-01), Yoshizaki et al.
patent: 0 448 181 (1991-09-01), None
patent: 0 628 639 (1994-12-01), None
patent: 0 785 276 (1997-07-01), None
patent: 0 791 359 (1997-08-01), None
patent: 0 811 384 (1997-12-01), None
patent: 02-188600 (1990-07-01), None
patent: 7-324097 (1995-12-01), None
patent: 8-99996 (1996-04-01), None
patent: 8-208514 (1996-08-01), None
patent: 8-50829 (1996-09-01), None
patent: 8-245414 (1996-09-01), None
patent: 8-311098 (1996-11-01), None
patent: 9-235276 (1997-09-01), None
patent: 9-235276 (1997-09-01), None
patent: WO 95/09873 (1995-04-01), None
patent: WO 95/13086 (1995-05-01), None
patent: WO 95/34320 (1995-12-01), None
patent: WO 96/00081 (1996-01-01), None
patent: WO 96/33735 (1996-10-01), None
patent: WO 96/38481 (1996-12-01), None
patent: WO 96/40966 (1996-12-01), None
patent: WO 96/40966 (1996-12-01), None
patent: WO 97/24340 (1997-07-01), None
patent: WO 97/38104 (1997-10-01), None
patent: WO 98/25971 (1998-06-01), None
patent: WO 98/28001 (1998-07-01), None
patent: WO 99/64069 (1999-12-01), None
patent: WO 2004/096273 (2004-11-01), None
Chuntharapai et al. Methods in Enzymology, vol. 288, pp. 15-27.
Igaku, vol. 51, No. 10, 1996, pp. 111-121, with Partial Translation.
Jpn. J. Clin. Immun., vol. 20, No. 2, 1997, pp. 87-94.
Powrie et al., “Inhibition of Th1 Responses Prevents Inflammatory Bowel Disease in scid Mice Reconstituted With CD45Rbhi CD4+ T Cells”, Immunity, vol. 1:553-562, (1994).
Takagi et al., “Blockage Of Interleukin-6 Receptor Ameliorates Joint Disease in Murine Collagen-Induced Arthritis”, Arthritis Reheumatism, vol. 41(12):2117-2121, (1998).
Mitsuyama et al., “Soluble Interleukin-6 Receptors in Inflammatory Bowel Disease; Relation To Circulating Interleukin-6”, Gut, vol. 36:45-49, (1995).
Van Dullemen et al., “Treatment Of Crohn's Disease With Anti-Tumor Necrosis Factor Chimeric Monoclonal Antibody (cA2)”, Gastroenterology, vol. 109:129-135, (1995).
Sasajima et al., “Changes in Serum Cytokine Profile During Treatment of Ulcerative Colitis”, Journal of Gastroenterology and Hepatology, Dec. 1997, p. A274, vol. 12, No. SUPPL., XP-001105732.
Funakoshi et al., “Spectrum of Cytokine Gene Expression in Intestinal Mucosal Lesions of Crohn's Disease and Ulcerativre Colitis”, Digestion, Jan. 1998, pp. 73-78, vol. 59, No. 1, Basel, China, XP-001064174.
Tateishi et al., “Role of Cytokines in Experimental Colitis: Relation to Intestinal Permeability”, Digestion, 1997, pp. 271-281, vol. 58, No. 3, Basel, China, XP-001095980.
Seidman et al., “Nutritional Issues in Pediatric inflammatory Bowel Disease”, Journal of Pediatric Gastroenterology and Nutrition, 1991, pp. 424-438, vol. 12, No. 4, Raven Press, Ltd., New York, XP-001105792.
Rogler et al., “Cytokines in Inflammatory Bowel Disease,” World J. Surg. vol. 22, No. 4, Apr. 1998, pp. 382-389.
Kmiec, “Cytokines in Inflammatory Bowel Disease,” Arch. Immunol. Ther. Exp. (Warsz), vol. 46, No. 3, 1998, pp. 143-155.
Hogezand et al., “Selective Immunomodulation in Patients With Inflammatory Bowel Disease-Future Therapy or Reality?” Neth. J. Med. Feb. 1996, vol. 48, No. 2, pp. 64-67.
Harrison, Paul, et al., Inhibition of the acute-phase response in vivo by anti-gp130 monoclonal antibodies,British Journal of Haematology, 1996, pp. 443-451, vol. 95, Blackwell Science Ltd., Oklahoma City, Oklahoma, USA.
Atreya et al., “Blockade of interleukin 6transsignaling suppresses T-cell resistance against apoptosis in chronic intestinal inflammation: Evidence in Crohn disease and experimental colitis in vivo,” Nature Medicine, May 2000, 6(5):583-588.
Gaillard et al., “Identification of a novel antigenic structure of the human receptor for interleukin-6 involved in the interaction with the glycoprotein 130 chain,” Immunology, 1996, 89:135-141.
Grottrup-Wolfers et al., “Elevated cell-associated levels of interleukin 1β and interleukin 6 in inflamed mucosa of inflammatory bowel disease,” European Journal of Clinical Investigation, 1996, 26:115-122.
Holub et al., “Increased Interleukin-6 Levels, Interkeukin-6 Receptor and gp130 Expression in Peripheral Lymphocytes of Patients with Inflammatory Bowel Disease,” Scand. J. Gastorenterol., 1998, 33 Suppl., 223:47-50.
Ito et al., “A Pilot Randomized Trial of a Human Anti-Interleukin-6 Receptor Monoclonal Antibody in Active Crohn's Disease,” Gastroenterology, 2004, 126(4):989-996.
Ito et al., “Anti-IL-6 receptor monoclonal antibody inhibits leukocyte recruitment and promotes T-cell apoptosis in a murine model of Crohn's disease,” J. Gastroenterol., 2002, 37(Supp. 14):56-51.
Ito et al., “IL-6 and Crohn's Disease,” Current Drug Targets—Inflammation & Allergy, 2003, 2(2):125130.
Jones et al., “Mucosal Interleukin-6 Secretion in Ulcerative Colitis,” Scand. J. Gastroenterol., 1994, 29:722-728.
Kalai et al., “Analysis of the mechanism of action of anti-human interleukin-6 and anti-human interleukin-6 receptor-neutralising monoclonal antibodies,” Eur. J. Biochem., 1997, 249:690-700.
Kiberd, Bryce A., “Interleukin-6 Receptor Blockage Ameliorates Murine Lupus Nephritis,” Journal of the American Society of Nephrology, 1993, 4(1):58-61.
Kishimoto, Tadamitsu, “Interleukin-6 and its Receptor in Autoimmunity,” Journal of Autoimminuty, 1992, 5(Supp. A):123-132.
Kitani et al., “Autostimulatory effects of IL-6 on excessive B cell differentiation in patients with systemic lupus erythematosus: analysis of IL-6 production and IL-6R expression,” Clin. Exp. Immunol, 1992, 88:75-83.
Kusugami et al., “Elevation of Interleukin-6 in Inflammatory Bowel Disease is Macrophage- and Epithelial Cell-Dependent,” Digestive Diseases and Sciences, May 1995, 40(5):949-959.
Nagafuchi et al., “Constitutive Expression of IL-6 Receptors and Their Role in the Excessive B Cell Function in Patients with Systemic Lupus Erythematosus,” J. Immunol., Dec. 1, 1993, 151(11):6525-6534.
Stevens et al., “Tumor Necrosis Factor-α, Interleukin-1β, and Interleukin-6 Expression in Inflammatory Bowel Disease,” Digestive Diseases and Sciences, Jun. 1992, 37(6):818-826.
Suzuki et al., “Anti-murine IL-6 receptor antibody inhibits IL-6 effects in vivo,” Immunology Letters, 1991, 30:17-22.
Vandenabeele et al., “Increased IL-6 Production and IL-6-Mediated Ig Secretion in Murine Host-vs-Graft Disease,” J. Immunol., May 1, 1993, 150(9):4179-4187.
Summons to Attend Oral Proceedings in Opposition against EP 99907951.0, Apr. 7, 2010, 11 pages.
Bellomo, R., “The Cytokine Network in the Critically Ill,” Anaesthesia and Intensive Care, Aug. 1992, 20(3):388-302.
Ulich et al., “Intratracheal Injection of Endotoxin and Cytokines,” American Journal of Pathology, May 1991, 138(5):1097-1101.
Office Action issued on Aug. 3, 2010, in corresponding Japanese Patent Application No. 20070245410, 3 pages.

Affiliated with

Also associated with

Rating

Preventive or therapeutic agent for inflammatory bowel... does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Preventive or therapeutic agent for inflammatory bowel..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Preventive or therapeutic agent for inflammatory bowel... will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-4237004